1 February 2016 in International Journal for Vitamin and Nutrition Research
Inflammatory bowel disease (IBD) is an inflammatory disorder involving colitis. Lycopene is a naturally occurring carotenoid that has attracted considerable attention as a potential chemopreventive agent. The impact of lycopene on colitis is currently unknown. The aim of this study was to investigate the protective effects of lycopene in a rat model of colitis induced by acetic acid. The animals were randomly divided into the following five groups: the control group, colitis group, colitis + sulfasalazine group as a positive control group, colitis + lycopene and lycopene groups. Colonic mucosal injury was assessed by biochemical and histopathological examinations. Malondialdehyde (MDA), superoxide dismutase (SOD) activity, total antioxidant status (TAS), ceruloplasmin (CPN), total sialic acid and iron (Fe) levels were evaluated in blood samples. MDA, SOD, TAS and DNA fragmentation levels were also measured in colon tissues. MDA (p < 0.05), total sialic acid (p < 0.05) and DNA fragmentation levels (p < 0.01) were significantly higher, and the activity of the antioxidant enzyme were lower in the colitis group than in the control group. Treatments with lycopene in the colitis decreased MDA, total sialic acid and DNA fragmentation levels, while SOD activity (p < 0.05), TAS (in colon p < 0.05; in serum p < 0.01), CPN (p < 0.05) and Fe levels (p < 0.05) were significantly increased. The histopathological evaluation also confirmed the foregoing findings. Treatment with lycopene ameliorated the biochemical and pathological alterations caused by colitis. The results obtained in this study indicate that lycopene may exert protective effects in experimental colitis and might, therefore, be useful for treatment of IBD.
1 September 2025 in Acta Pharmaceutica
This study aimed to investigate the anticancer effects and underlying mechanisms of an ethanolic extract of Lavandula stoechas L. flowers (LsHE) on colorectal cancer. The extract demon strated high phenolic content (230.31 ± 11.28 mg GAE g – ¹ dm) and strong antioxidant activity. HPLC analysis identified rosmarinic acid and quercetin as major constituents. HT-29 colorectal carcinoma cells and HEK-293 healthy kidney epithelial cells were treated with LsHE for 48 h. The concentration of LsHE required to inhibit 50 % of HT-29 cell viability was found to be 86.37 ± 3.07 µg mL –1 , whereas a higher concentration of 131.30 ± 9.33 µg mL –1 was observed for HEK-293 cells. In HT-29 cells, flow cytometry analysis revealed increased early (9.7 %) and late (6.8 %) apoptotic populations following LsHE treatment ( p < 0.0001). qRT-PCR analysis showed significant upregulation of TP53 and CASP3 compared to the untreated group ( p < 0.05 and p < 0.01, resp.), while BAX expression was unexpectedly downregulated. These findings suggest that LsHE may trigger caspase-3-dependent apoptosis through a p53-mediated mechanism, potentially independent of the BAX/BCL-2 pathway. In conclusion, the present in vitro study highlights the potential of LsHE as a natural agent that still exerts some cytotoxicity toward normal epithelial cells and pro-apoptotic activity in colorectal cancer cells. Our findings provide a molecular basis for further in vivo studies to evaluate the possible therapeutic potential and mechanistic relevance of LsHE in CRC chemoprevention.